pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·3h ago·1 min read
save

Omada Health posts first profitable quarter and prepares CEO succession

Sep 15, 2026·read at Endpoints ↗EarningsPositive

Omada Health, a digital health company, completed its IPO a little over a year ago and has now posted its first profitable quarter, achieved in the spring.

The profitability marks a milestone for the firm, which has been focusing on scaling its chronic disease management platform.

With the financial results in hand, the board is preparing for its inaugural CEO transition, appointing Wei-Li Shao, who joined the company recently, to take over leadership.

source

This writeup was produced by pharmadog from original reporting by Endpoints.

Original headline: “Why Omada is staying in its lane”

read at Endpoints ↗
80 words · retrieved 1h ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

no entities indexed yet

related stories

  • 11m agoFDA approves first radioligand generic, setting up rivalry with NovartisEndpoints
  • 42m agoCentric Compounding recalls three injectables over contaminationEndpoints
  • 1h agoSionna cuts nearly half of staff as it lines up second attempt at cystic fibrosisEndpoints
  • 1h agoRocket's Danon plans; Novo leaves Ascendis; Lilly's latest dealEndpoints
  • 2h agoGSK to wind down German vaccine factory due to lack of demandEndpoints